Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.43 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.41 |
| ▸ | CASP2 | P42575 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25878371 | 0.89 | NOD1 (0.52) | — | |
| SCHEMBL25878429 | 0.89 | NOD1 (0.52) | — | |
| SCHEMBL25878400 | 0.89 | NOD1 (0.52) | — | |
| SCHEMBL13120985 | 0.88 | CASP2 (0.57) | EPHX2KDM4EFAAHMEN1KMT2A | |
| SCHEMBL25878486 | 0.88 | CASP2 (0.57) | EPHX2KDM4EFAAHMEN1KMT2A | |
| SCHEMBL12666256 | 0.88 | EPHX2 (0.54) | EPHX2ADRA1AKDM4EPRMT1FAAH | |
| SCHEMBL12891255 | 0.88 | EPHX2 (0.54) | EPHX2ADRA1AKDM4EPRMT1FAAH | |
| SCHEMBL13706976 | 0.88 | EPHX2 (0.54) | EPHX2ADRA1AKDM4EPRMT1FAAH | |
| SCHEMBL16944361 | 0.88 | EPHX2 (0.54) | EPHX2ADRA1AKDM4EPRMT1FAAH | |
| SCHEMBL12891252 | 0.88 | EPHX2 (0.54) | EPHX2ADRA1AKDM4EPRMT1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7893017-B2 | Acylation; point mutations; site-directed mutagenesis; hyperglycemia; diabetes | NOVO NORDISK A/S (DK) | 2011-02-22 | — | — | US | disclosed |
| US-20080182785-A1 | Protracted Glp-1 Compounds | NOVO NORDISK A/S (DK) | 2008-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182785-A1 | Protracted Glp-1 Compounds | GLP1R, GIPR, GRPR | EPHX2 4719/4885ADRA1A 808/4885KDM4E 4011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.